Stock Scorer

CytomX Therapeutics, Inc. (CTMX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 20M 40M 60M Q3 '21: 17.6M Q4 '21: 11.1M Q1 '22: 9M Q2 '22: 12.9M Q3 '22: 11.1M Q4 '22: 20.1M Q1 '23: 23.5M Q2 '23: 24.7M Q3 '23: 26.4M Q4 '23: 26.6M Q1 '24: 41.5M Q2 '24: 25.1M Q3 '24: 33.4M Q4 '24: 38.1M Q1 '25: 50.9M Q2 '25: 18.7M Q3 '25: 6M Q4 '25: 663K Q1 '26: 10.3M Q2 '26: 1.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -22.6M Q4 '21: -34.9M Q1 '22: -32.1M Q2 '22: -30.1M Q3 '22: -29.7M Q4 '22: -9.5M Q1 '23: -5.7M Q2 '23: -3.3M Q3 '23: 3.1M Q4 '23: -606K Q1 '24: 11.7M Q2 '24: -8.5M Q3 '24: 4.1M Q4 '24: 17.7M Q1 '25: 22.6M Q2 '25: -1.3M Q3 '25: -15.8M Q4 '25: -27.9M Q1 '26: -19.7M Q2 '26: -23.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -22.6M Q4 '21: -34.8M Q1 '22: -32M Q2 '22: -29.5M Q3 '22: -29.1M Q4 '22: -8.8M Q1 '23: -3.3M Q2 '23: -1.1M Q3 '23: 3M Q4 '23: 837K Q1 '24: 13.8M Q2 '24: -6.5M Q3 '24: 5.7M Q4 '24: 18.9M Q1 '25: 23.5M Q2 '25: -154K Q3 '25: -14.2M Q4 '25: -26.5M Q1 '26: -18.2M Q2 '26: -20.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -29.7M Q4 '21: -31.2M Q1 '22: -41.3M Q2 '22: -34.2M Q3 '22: -33.8M Q4 '22: -1.4M Q1 '23: 9.3M Q2 '23: -25.2M Q3 '23: -18.2M Q4 '23: -22M Q1 '24: -26M Q2 '24: -19.5M Q3 '24: -20.7M Q4 '24: -19.9M Q1 '25: -21M Q2 '25: -15.8M Q3 '25: -15.5M Q4 '25: -23.2M Q1 '26: -25.5M Q2 '26: -18.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -30M Q4 '21: -31.4M Q1 '22: -42M Q2 '22: -34.6M Q3 '22: -34.3M Q4 '22: -1.6M Q1 '23: 9.3M Q2 '23: -25.7M Q3 '23: -18.3M Q4 '23: -22.2M Q1 '24: -26.2M Q2 '24: -19.6M Q3 '24: -20.7M Q4 '24: -20M Q1 '25: -21.2M Q2 '25: -15.8M Q3 '25: -15.7M Q4 '25: -23.4M Q1 '26: -25.5M Q2 '26: -18.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q3 '20: 46.2M Q4 '20: 46.6M Q1 '21: 61M Q2 '21: 65.1M Q3 '21: 65.2M Q4 '21: 65.3M Q1 '22: 65.4M Q2 '22: 65.5M Q3 '22: 65.9M Q1 '23: 66.2M Q2 '23: 66.5M Q3 '23: 81M Q1 '24: 82.6M Q2 '24: 84.9M Q3 '24: 85.2M Q1 '25: 87.2M Q2 '25: 129.1M Q3 '25: 165M Q1 '26: 177.3M Q2 '26: 218.9M Q4 '20 Q3 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45.00 -30.00 -15.00 0.00 15.00 30.00 45.00 Q2 '15: -25.19 Q3 '15: -34.59 Q4 '15: -4.90 Q1 '16: 2.22 Q2 '16: 9.39 Q3 '16: 23.25 Q4 '16: -1.62 Q1 '17: -1.41 Q2 '17: -1.71 Q2 '15 Q4 '15 Q2 '16 Q4 '16 Q2 '17

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for CTMX: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.